We're on a mission to fulfill the promise of genomic medicine for all patients
With our breakthrough all-RNA PRINT™ platform, we're forging new frontiers for what's possible in the treatment of both chronic and rare diseases.
About Us
Today, only a small fraction of patients are able to take advantage of genomic medicine to treat their disease. At Addition, we're working to create a much different tomorrow.
With our breakthrough all-RNA, non-viral, lipid nanoparticle (LNP)-based PRINT (Precise RNA-Mediated INsertion of Transgenes) platform, we aim to develop safer, durable, one-time therapies, overcoming limitations of current gene therapies.
Leveraging our world-class platform, we are advancing a robust pipeline of PRINTed medicines that have the potential to address significant unmet needs - and fundamentally redefine how chronic and rare diseases are treated.
We're focused on progress for patients
Platform
Our team of highly skilled scientists and engineers have built our world-class PRINT platform.
Pipeline
We're now advancing a preclinical pipeline of PRINTed medicines for chronic and rare indications.
Promise
Our programs, including ones supported by pharmaceutical companies and the Gates Foundation, demonstrate the broad applicability of the PRINT platform.
